ALVO
HealthcareAlvotech · Drug Manufacturers - Specialty & Generic · $1B
What is Alvotech?
Alvotech is a global biosimilar medicines company focused on developing and manufacturing lower-cost alternatives to complex biologic drugs. Headquartered in Luxembourg and publicly listed since 2022, it targets high-value therapeutic areas including autoimmune disease, oncology, and eye disorders.
Alvotech develops biosimilar versions of established biologic medicines, aiming to bring more affordable treatment options to patients worldwide. The company earns revenue primarily through commercializing approved biosimilars and licensing agreements with regional partners. Its pipeline spans late-stage and early-phase programs targeting inflammatory conditions, cancer, and eye diseases. Rather than discovering novel drugs, Alvotech replicates the clinical profile of proven biologics — a capital-intensive but potentially high-reward model.
Alvotech was established in 2022 and is headquartered in Luxembourg.
- AVT02 — biosimilar to Humira for inflammatory conditions including rheumatoid arthritis
- AVT04 — biosimilar to Stelara for psoriatic arthritis and Crohn's disease
- AVT06 — biosimilar to Eylea for age-related macular degeneration and diabetic retinopathy
- AVT23 — late-stage biosimilar to Xolair for nasal polyps
- AVT03 — pre-clinical biosimilar to Xgeva and Prolia for bone-related cancer complications
Is ALVO a Good Stock to Buy?
UQS Score rates ALVO as Below Average overall, reflecting meaningful structural challenges alongside one standout strength.
Alvotech's Growth pillar is rated Strong — the clearest bright spot in its profile. A maturing pipeline with multiple programs across late-stage and early-phase development supports a credible near-term revenue expansion story, particularly as biosimilar adoption accelerates in key markets.
However, the Quality, Moat, and Risk pillars are all rated Weak, signaling concerns around financial durability, competitive differentiation, and balance-sheet resilience. Valuation is rated Neutral, offering little cushion against execution risk.
Pro members can view the full pillar breakdown and underlying financial metrics to assess whether ALVO's growth trajectory justifies its risk profile. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ALVO pay dividends?
No — Alvotech does not currently pay a dividend.
Alvotech does not currently pay a dividend. As a clinical-stage and early-commercial biosimilar company, capital is directed toward pipeline development, regulatory approvals, and manufacturing scale-up. Income-focused investors should look elsewhere; those with a growth orientation may find the reinvestment rationale more relevant to their thesis.
When does ALVO report earnings?
Alvotech reports earnings on a quarterly cadence, consistent with US-listed equities.
Revenue trajectory has been shaped by the commercial rollout of its lead biosimilar programs and evolving partnership arrangements. Given the Weak Quality and Risk pillar ratings, profitability metrics remain under pressure relative to more established healthcare peers.
For the most recent quarter's results and guidance, visit Alvotech's investor relations page directly.
ALVO Price History
-57.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Alvotech?
Based on Alvotech's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ALVO Long-term Outlook
Alvotech's Strong Growth pillar suggests meaningful pipeline-driven revenue expansion is plausible over the medium term, particularly as additional biosimilar approvals convert into commercial revenue. That said, the Weak Risk pillar introduces real uncertainty around execution, financing, and regulatory timelines. The Neutral Valuation pillar indicates the market has partially priced in growth expectations, leaving limited room for disappointment.
Growth drivers
- Expanding biosimilar pipeline with multiple programs approaching or in late-stage development
- Growing global demand for affordable alternatives to high-cost biologic medicines
- Licensing and commercialization partnerships that extend geographic reach without proportional capital outlay
Key risks
- Weak Risk pillar signals balance-sheet and operational vulnerabilities typical of early-commercial biotech
- Biosimilar markets face pricing pressure and slower-than-expected adoption in some regions
- Regulatory delays or manufacturing setbacks could disrupt the commercialization timeline
ALVO vs Peers
Alvotech operates in a competitive healthcare landscape alongside companies pursuing differentiated drug development and specialty pharmaceutical strategies.
Evotec focuses on drug discovery partnerships and contract research rather than biosimilar development, targeting a broader range of therapeutic modalities.
Tilray operates across cannabis and beverage alcohol, representing a very different risk and revenue profile compared to Alvotech's biosimilar-focused model.
Collegium specializes in responsible pain management medicines, with a commercial-stage portfolio that contrasts with Alvotech's pipeline-heavy biosimilar approach.
Frequently Asked Questions
What does Alvotech do?
Alvotech develops and manufactures biosimilar medicines — lower-cost alternatives to complex biologic drugs. Its programs target autoimmune conditions, eye disorders, bone-related cancer complications, and other serious diseases. The company operates a pipeline spanning pre-clinical through late-stage development, with several products already commercialized through regional licensing partners.
Does ALVO pay dividends?
No, Alvotech does not pay a dividend. The company is in an active investment phase, directing resources toward pipeline development, regulatory submissions, and manufacturing capacity. Investors seeking regular income should consider this before adding ALVO to a dividend-oriented portfolio.
When does ALVO report earnings?
Alvotech follows a quarterly earnings reporting cadence, standard for US-listed companies. Specific dates are not available through our data source. For confirmed upcoming report dates, check Alvotech's official investor relations page.
Is ALVO a good stock to buy?
UQS Score rates ALVO as Below Average overall. Its Strong Growth pillar stands out, but Weak ratings across Quality, Moat, and Risk highlight real structural concerns. Whether the growth potential outweighs those risks depends on an investor's individual risk tolerance and time horizon. The full pillar breakdown is available to Pro members.
Is ALVO overvalued?
The UQS Valuation pillar for ALVO is rated Neutral, suggesting the market has priced in a balanced view of its prospects — neither deeply discounted nor obviously stretched. Given the Weak Risk and Quality ratings, a Neutral valuation leaves limited margin of safety if execution falters.
How does ALVO compare to its competitors?
Alvotech's biosimilar-focused model is distinct from peers like Evotec, which emphasizes drug discovery partnerships, and Collegium, which operates a commercial pain management portfolio. Tilray's cannabis and beverage focus is even further removed. ALVO's differentiation lies in its concentrated bet on biosimilar development across multiple therapeutic areas.
What is ALVO's market cap bracket?
Alvotech is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but typically carries greater volatility and liquidity risk compared to large-cap or mega-cap healthcare peers.
Who founded Alvotech?
Alvotech's founding history and key executives are publicly documented on the company's official website and in its regulatory filings. The company became publicly listed in 2022 and is headquartered in Luxembourg.
Is ALVO a long-term quality stock?
As a long-term quality indicator, ALVO's profile is mixed. The Strong Growth pillar points to pipeline-driven expansion potential, but Weak scores in Quality, Moat, and Risk suggest the business has not yet demonstrated the durability and competitive insulation typically associated with high-quality long-term holdings. Pro members can explore the full analysis.
What is the main competitive advantage of Alvotech?
Alvotech's primary competitive positioning comes from its specialized biosimilar manufacturing capabilities and a diversified pipeline across multiple high-value therapeutic areas. However, the UQS Moat pillar is rated Weak, indicating that durable competitive advantages relative to sector peers have not yet been firmly established.
What sector does ALVO belong to?
Alvotech operates in the Healthcare sector, specifically within the biotechnology and biosimilar medicines space. It sits at the intersection of pharmaceutical development and biologics manufacturing, targeting markets where branded biologic drugs face patent expiration and biosimilar competition is growing.
Is ALVO a growth stock or value stock?
Based on UQS pillar ratings, ALVO leans toward the growth category — its Growth pillar is rated Strong, while Valuation is Neutral. It does not exhibit the characteristics of a traditional value stock. Investors drawn to pipeline-stage growth stories may find it more relevant than those seeking undervalued, cash-generative businesses.
Unlock Full ALVO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access underlying financial metrics driving each pillar
- ✓Compare ALVO against sector peers on quality and risk
- ✓See valuation context relative to biosimilar competitors
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
ALVO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 55.9 | 34.3 | 27.0 | 89.2 | 70.7 | 80.6 | +11.4 |
| May 22, 2026 | 44.5 | 22.2 | 27.0 | 89.2 | 36.6 | 58.8 | -0.1 |
| May 21, 2026 | 44.6 | 22.2 | 27.0 | 89.2 | 36.6 | 59.4 | 0.0 |
| May 20, 2026 | 44.6 | 22.2 | 27.0 | 89.2 | 36.6 | 59.6 | 0.0 |
| May 19, 2026 | 44.6 | 22.2 | 27.0 | 89.2 | 36.6 | 59.8 | 0.0 |
| May 17, 2026 | 44.6 | 22.2 | 27.0 | 89.2 | 36.6 | 59.3 | +0.1 |
| May 16, 2026 | 44.5 | 22.2 | 27.0 | 89.1 | 36.6 | 59.3 | +0.1 |
| May 15, 2026 | 44.4 | 22.2 | 27.0 | 89.1 | 36.6 | 58.4 | +0.3 |
| May 14, 2026 | 44.1 | 22.2 | 27.0 | 89.1 | 36.6 | 56.8 | -0.2 |
| May 13, 2026 | 44.3 | 22.2 | 27.0 | 89.1 | 36.6 | 57.6 | +0.1 |
ALVO — Pillar Breakdown
Quality
— 34.3/100 (25%)Alvotech currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 89.2/100 (20%)Alvotech is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 70.7/100 (15%)Alvotech maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 80.6/100 (15%)Alvotech appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 27/100 (25%)Alvotech operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ALVO.
Score Composition
Financial Data
More Stock Analysis
How is the ALVO UQS Score Calculated?
The UQS (Unified Quality Score) for Alvotech is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Alvotech's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Alvotech is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.